BTCY BIOTRICITY INC.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1630113 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.7%
TTM net income YoY38.0%
TTM EPS YoY-4.9%
Revenue 3-yr CAGR14.9%
Net income 3-yr CAGR—
Margins
Gross margin81.8%
Operating margin9.7%
Net margin-16.7%
FCF margin—
EBITDA margin9.7%
Returns
ROE—
ROA-45.2%
ROIC (approx.)—
Asset turnover2.71x
Leverage & solvency
Liabilities / assets662.7%
Debt / equity—
Current ratio0.15x
Interest coverage0.49x
Cash quality & payout
Operating cash flow / net income0.09x
Accruals ratio-41.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.33M | $4.28M | $4.25M | $3.99M | $3.89M | $3.87M | $3.70M | $3.62M |
| Cost of revenue | $725,733 | $746,136 | $851,608 | $736,343 | $704,297 | $757,193 | $724,416 | $855,140 |
| Gross profit | $3.61M | $3.53M | $3.40M | $3.25M | $3.18M | $3.12M | $2.98M | $2.76M |
| R&D expense | $884,501 | $673,444 | $841,669 | $623,567 | $602,798 | $696,163 | $572,567 | $551,216 |
| SG&A expense | $2.39M | $2.70M | $1.86M | $2.19M | $2.30M | $2.14M | $3.26M | $2.38M |
| Operating income | $338,715 | $158,068 | $694,557 | $440,915 | $273,819 | $281,945 | -$855,466 | -$168,982 |
| Interest expense | $854,081 | $851,753 | $840,938 | $810,339 | $860,419 | $850,254 | $891,752 | $849,538 |
| Pretax income | -$808,161 | -$959,468 | -$324,182 | -$717,067 | -$690,913 | -$671,977 | -$1.94M | -$1.23M |
| Net income | -$808,161 | -$959,468 | -$324,182 | -$717,067 | -$690,913 | -$671,977 | -$1.94M | -$1.23M |
| EBITDA | $340,204 | $159,556 | $696,045 | $442,403 | $275,308 | $283,433 | -$853,978 | -$167,493 |
| EPS (basic) | -0.05 | -0.05 | — | -0.04 | -0.03 | -0.03 | — | -0.05 |
| EPS (diluted) | -0.05 | -0.05 | — | -0.04 | -0.03 | -0.03 | — | -0.05 |
| Weighted avg. shares (diluted) | 20.75M | 23.10M | — | 27.59M | 26.77M | 26.28M | — | 24.23M |
| Balance sheet | ||||||||
| Cash & equivalents | $268,998 | $466,503 | $149,789 | $256,357 | $308,460 | $391,292 | $365,145 | $509,601 |
| Receivables | $2.55M | $2.40M | $2.93M | $1.58M | $2.10M | $1.86M | $1.66M | $1.24M |
| Inventory | $1.28M | $1.43M | $1.34M | $1.97M | $2.26M | $1.78M | $1.56M | $1.57M |
| Current assets | $5.86M | $5.60M | $5.86M | $4.98M | $5.54M | $5.14M | $4.64M | $4.86M |
| PP&E, net | $669 | $2,157 | $3,646 | $5,134 | $6,622 | $8,111 | $9,599 | $11,087 |
| Total assets | $6.12M | $6.02M | $6.45M | $5.69M | $6.32M | $6.04M | $5.64M | $5.99M |
| Current liabilities | $38.15M | $37.34M | $37.14M | $23.80M | $23.61M | $21.81M | $20.64M | $21.14M |
| Total liabilities | $40.55M | $39.72M | $39.41M | $38.21M | $37.98M | $36.84M | $35.66M | $35.78M |
| Shareholders' equity | -$35.99M | -$35.41M | -$34.68M | -$34.24M | -$33.41M | -$32.80M | -$32.01M | -$31.94M |
| Shares outstanding | 21.63M | 20.07M | 28.60M | 27.81M | 26.79M | 26.57M | 26.08M | 24.39M |
| Cash flow statement | ||||||||
| Operating cash flow | $3,521 | $507,227 | -$20,905 | -$740,291 | $415,630 | -$373,389 | -$400,785 | -$88,093 |
| Financing cash flow | -$198,525 | -$190,935 | -$91,546 | $721,325 | -$507,748 | $435,705 | $165,020 | $424,960 |
| Depreciation & amortization | $1,489 | $1,488 | $1,488 | $1,488 | $1,489 | $1,488 | $1,488 | $1,489 |
| Stock-based compensation | $0 | $339,970 | $7,695 | $6,001 | $6,001 | $5,935 | $1.29M | $56,939 |
Free plan shows the latest 8 periods; Pro shows all 53 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.